A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira#174;) in patients with active rheumatoid arthritis

Details

Language :

English

ISSN :

14786354

Volume :

19

Database :

Complementary Index

Journal :

Arthritis Research & Therapy

Publication Type :

Academic Journal

Accession number :

124258066

Full Text :

https://doi.org/10.1186/s13075-017-1371-4